What is the FDA’s 6-month pediatric exclusivity extension?
FDA’s pediatric exclusivity is an incentive that can extend the exclusivity period for certain drug products by 6 months when the sponsor completes required pediatric studies. The extension is tied to FDA approval pathways and pediatric study obligations under FDA programs that govern pediatric assessment. [1]
How does the 6-month extension work, and what triggers it?
A company must submit pediatric study information in a way that satisfies FDA requirements tied to pediatric exclusivity. When FDA determines the pediatric assessment has met the program’s conditions for the relevant drug/exclusivity, the applicable exclusivity period can receive the additional 6 months. [1]
Which products are eligible for this pediatric exclusivity?
Pediatric exclusivity generally applies to eligible drugs for which FDA has determined pediatric studies are required/appropriate under the pediatric framework that supports the exclusivity incentive. The specific eligibility depends on the product’s approval context and the type of exclusivity the drug has. [1]
Does the 6-month period extend marketing exclusivity, patent life, or both?
The pediatric exclusivity extension extends FDA-granted exclusivity (a marketing protection mechanism), not the underlying patent term itself. This can still affect when competitors may be able to market relying on certain legal/regulatory pathways because FDA exclusivity can block approval or marketing for some time. [1]
When does the 6-month extension start?
The 6-month extension is added to the end of the applicable FDA exclusivity period for the product once FDA grants the pediatric exclusivity based on completion of the required pediatric studies. The exact start date therefore depends on the timing of the underlying exclusivity expiration for that drug. [1]
How does pediatric exclusivity affect generics and biosimilars?
Because it extends FDA exclusivity, the 6-month add-on can delay the ability of certain follow-on products to enter the market that would otherwise rely on the original product’s exclusivity protection window. The practical impact depends on the specific application type and what legal basis the follow-on product is using, but pediatric exclusivity is designed to protect against early competition while pediatric data are generated and assessed. [1]
What information do companies usually need to submit for pediatric exclusivity?
The company must conduct pediatric studies and submit results to FDA in the required format and within the program’s expectations so FDA can determine whether the pediatric assessment requirements for the exclusivity incentive have been met. [1]
Where can I find the official FDA rules for pediatric exclusivity?
FDA describes pediatric exclusivity and its rules in its pediatric incentives materials and related guidance/regulatory information. [1]
Sources:
1. https://www.fda.gov/drugs/administration-approval-process-drugs/pediatric-exclusivity